Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK2 and CDK9, which are involved in cell cycle regulation and transcription. This compound shows promise in oncology for targeting cancer cells by disrupting uncontrolled cell proliferation. It has demonstrated antiproliferative activity in various tumor cell lines, making it a candidate for development in targeted cancer therapies. Its structure allows for high binding affinity to the ATP-binding site of CDKs, enhancing its inhibitory effect. Also investigated for potential use in treating viral infections due to its impact on host cell transcription mechanisms.